Finch Therapeutics Group Stock Current Valuation
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Valuation analysis of Finch Therapeutics helps investors to measure Finch Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Finch Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Finch Therapeutics is based on 3 months time horizon. Increasing Finch Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Finch Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Finch Pink Sheet. However, Finch Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.51 | Real 8.22 | Hype 8.51 | Naive 8.56 |
The intrinsic value of Finch Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Finch Therapeutics' stock price.
Estimating the potential upside or downside of Finch Therapeutics Group helps investors to forecast how Finch pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Finch Therapeutics more accurately as focusing exclusively on Finch Therapeutics' fundamentals will not take into account other important factors: Finch Therapeutics Group Company Current Valuation Analysis
Finch Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Finch Therapeutics Current Valuation | 10.74 M |
Most of Finch Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Finch Therapeutics Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Finch Therapeutics Group has a Current Valuation of 10.74 M. This is 99.93% lower than that of the Biotechnology sector and 99.77% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Finch Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Finch Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics of similar companies.Finch Therapeutics is currently under evaluation in current valuation category among its peers.
Finch Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Shares Owned By Insiders | 53.48 % | ||||
| Shares Owned By Institutions | 11.35 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K | ||||
| Gross Profit | (57.03 M) | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (74.75 M) | ||||
| Cash And Equivalents | 104.67 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 30.13 M | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 7.28 X | ||||
| Book Value Per Share | 11.86 X | ||||
| Cash Flow From Operations | (31.5 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (6.59) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 90.0 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 1.94 M | ||||
| Total Asset | 71 M | ||||
| Retained Earnings | (350.39 M) | ||||
| Working Capital | 21.76 M | ||||
| Net Asset | 71 M |
About Finch Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Finch Therapeutics Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Finch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Finch Therapeutics Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance |